-
公开(公告)号：US20200079856A1
公开(公告)日：2020-03-12
申请号：US16613579
申请日：2018-05-15
Applicant: Five Prime Therapeutics, Inc.
Inventor： Helen L. Collins , James Hnatyszyn , Hong Xiang , Xiang Zhang
IPC: C07K16/28 , A61P35/00 , A61K39/395 , A61K31/519 , A61K31/513 , A61K31/282 , A61P35/04 , A61K9/00
Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
-
公开(公告)号：US20200079848A1
公开(公告)日：2020-03-12
申请号：US16506754
申请日：2019-07-09
Inventor： Xiao Min Schebye , Diana Yuhui Chen , Andrew Rankin , Xiaodi Deng , Joseph Toth , Linda Liang , Michelle Minhua Han , Christine Bee , Hong-An Truong , Mark J. Selby , Nils Lonberg , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova , Alan J. Korman
IPC: C07K16/28 , A61K47/68 , A61K39/395 , A61K45/06 , G01N33/577 , G01N33/563 , A61P35/00
Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.
-
公开(公告)号：US20190202889A1
公开(公告)日：2019-07-04
申请号：US16354689
申请日：2019-03-15
Applicant: Five Prime Therapeutics, Inc.
Inventor： Thomas BRENNAN , David BELLOVIN , David BUSHA , Barbara SENNINO
IPC: C07K14/705 , A61K39/395 , A61K38/17 , C07K16/00 , A61K45/06 , C07K16/28
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39558 , A61K45/06 , C07K16/00 , C07K16/2803 , C07K2317/41 , C07K2319/03 , C07K2319/30
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
-
公开(公告)号：US20190125833A1
公开(公告)日：2019-05-02
申请号：US16095974
申请日：2017-04-24
Applicant: Five Prime Therapeutics, Inc. , Glaxosmithkline Intellectual Property Development Limited
Inventor： Aaron Curtis Hinken , Amy W. Hsu , Janine Powers , Warren James Rocque , Alan James Russell
CPC classification number: A61K38/1774 , A61P7/06 , A61P21/00 , A61P25/28 , C07K14/70503 , C07K2319/30
Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
-
公开(公告)号：US10016484B2
公开(公告)日：2018-07-10
申请号：US14357336
申请日：2012-11-13
Applicant: FIVE PRIME THERAPEUTICS, INC.
Inventor： Thomas Harding , Servando Palencia , Li Long , Kevin Hestir
IPC: A61K38/18 , C07K14/475 , A61K38/17 , A61K39/395 , A61K45/00 , A61K45/06 , C07K14/71 , C12Q1/6813 , C12Q1/686 , G01N33/50
CPC classification number: A61K38/179 , A61K39/395 , A61K45/00 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6813 , C12Q1/686 , G01N33/5005 , A61K2300/00
Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
-
Patent Agency Ranking
公开(公告)号：US20180094067A1
公开(公告)日：2018-04-05
申请号：US15680664
申请日：2017-08-18
Inventor： Brian Wong , Julie Hambleton , Robert Sikorski , Emma Masteller , Kevin Hestir , David Bellovin , Katherine E. Lewis
CPC classification number: C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
公开(公告)号：US20180085472A1
公开(公告)日：2018-03-29
申请号：US15564866
申请日：2016-04-12
Applicant: Five Prime Therapeutics, Inc.
Inventor： Emma Masteller , Thomas Brennan , David Bellovin , Kevin Baker , Brian Wong
CPC classification number: A61K47/6879 , A61K47/6851 , A61K51/1084 , A61K2039/507 , A61P35/00 , C07K16/2866 , C07K16/2878
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
-
公开(公告)号：US20170349643A1
公开(公告)日：2017-12-07
申请号：US15620211
申请日：2017-06-12
Applicant: Five Prime Therapeutics, Inc.
Inventor： Lewis T. Williams , Elizabeth Bosch , Stephen K. Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin G.P. Wong , Ge Wu , Hongbing Zhang
IPC: C07K14/71 , C07K16/28 , A61K45/06 , C07K17/08 , C07K14/765
CPC classification number: C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
公开(公告)号：US09695243B2
公开(公告)日：2017-07-04
申请号：US14924568
申请日：2015-10-27
Applicant: Five Prime Therapeutics, Inc.
Inventor： Justin Wong , Maximiliano Vasquez
IPC: C07K16/28 , C12N15/11 , C12N15/63 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2866 , A61K39/3955 , A61K39/39558 , A61K45/06 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/11 , C12N15/63
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
-
130.发明申请公开(公告)号：US20170145102A1
公开(公告)日：2017-05-25
申请号：US15358756
申请日：2016-11-22
Applicant: Five Prime Therapeutics, Inc.
Inventor： Kristen Pierce , Janine Powers , Servando Palencia , Robert Sikorski , Majid Ghoddusi , Kartik Krishnan
CPC classification number: C07K16/2863 , A61K2039/505 , A61K2039/507 , A61K2039/55 , C07K16/2818 , C07K16/2896 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K16/3038 , C07K16/3046 , C07K16/3069 , C07K16/3084 , C07K2317/34 , C07K2317/41 , G01N33/5091 , G01N33/57407 , G01N33/57446 , G01N33/57492 , G01N2333/71 , G01N2800/52
Abstract: Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
-
-
-
-
-
-
-
-
-
Search Results
138
records
(took 0.051 seconds)
